janvier 16, 2023

MORRISVILLE, N.C. – janvier 16, 2023 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, announced that it has entered into a partnership with Clinical Research Malaysia (CRM), expanding the Company’s clinical trial capabilities across a broader range of therapeutic areas in Malaysia.

The partnership is the first site network for Syneos Health in Malaysia, expanding its footprint in Asia Pac and enabling the Company and CRM to collaborate in bringing clinical research sites and industry partners together. This collaboration will help to deliver consistent quality for clinical trials, allow the sites to have the opportunity to participate in an increased volume of trials in the region, and harness best practices and insights from other research sites across the globe. The Catalyst Site Network Partnership offers biopharmaceutical customers a synergistic experience, while enabling sites, sponsors and patients to be more engaged throughout the entire clinical trial process.

“Our venture with CRM is part of Syneos Health’s global strategy to accelerate our clinical development impact in this rapidly growing and changing market,” said Dr. Ken J. Lee, General Manager and Regional Head, Clinical Development, APAC, Syneos Health. “This collaboration supports our strong customer first focus, bringing consistent delivery and quality to their programs and executing ‘fit for purpose’ solutions that address their unique and complex needs.”

Prior to the signing, the Minister of Health of Malaysia, Dr Zaliha Mustafa delivered her address, sharing her aspirations for the new collaboration. “This partnership is one of the many ongoing efforts by CRM to strengthen the country’s clinical research footprint. With more than 2,000 sponsored clinical research trials conducted since 2012 in Malaysia, this collaboration would unlock new opportunities for bettering the quality of clinical trials and discovery of new treatment and local drugs.”

About Syneos Health
Syneos Health® (Nasdaq:SYNH) est une organisation de solutions biopharmaceutiques entièrement intégrées et conçues pour accélérer la réussite des clients. Nous traduisons des perspectives cliniques, d’affaires médicales et commerciales uniques en résultats qui répondent aux réalités du marché actuel.  

Nous réunissons une équipe de professionnels talentueux qui travaillent dans plus de 110 pays et qui ont une connaissance approfondie des comportements des patients et des médecins, ainsi que de la dynamique du marché. 
Ensemble, nous partageons des connaissances, utilisons les dernières technologies et appliquons des pratiques commerciales de pointe pour accélérer la livraison d’importants traitements par nos clients aux patients. 

Syneos Health soutient une culture diversifiée, équitable et inclusive qui prend soin des collègues, des clients, des patients, des collectivités et de l’environnement.  

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.  

Syneos Investor Relations Contact:               
Ronnie Speight                                               
Senior Vice President, Investor Relations           
+1 919 745 2745                                             
[email protected]  

Syneos Press/Media Contact:
Gary Gatyas
Executive Director, External Communications
 +1 908 763 3428
[email protected]